Physician Fee Cuts Also a Possibility

Publication
Article
OncologyONCOLOGY Vol 15 No 10
Volume 15
Issue 10

As if the prospective Medicare cuts in payments for outpatient chemotherapy drugs were not troubling enough, there is another dark Medicare cloud. The American Medical Association (AMA) is predicting that Medicare may also cut physician

As if the prospective Medicare cuts in payments for outpatient chemotherapydrugs were not troubling enough, there is another dark Medicare cloud. TheAmerican Medical Association (AMA) is predicting that Medicare may also cutphysician fees across the board in 2002. A decision on that will not be madeuntil November, when the CMS presents final numbers for the Medicare EconomicIndex (MEI), an inflation adjustment, and the Sustainable Growth Rate (SGR),which describes how much under or over a preset target physicians’ bills toMedicare were in a given year. 

If physicians keep their billing below theincrease in the gross domestic product, then the MEI is increased, leading to ahigher fee "update." In the opposite scenario, the MEI is decreased.Based on preliminary forecasts, the AMA believes that physician fees could becut 2% to 3% in 2002. (That would be after increases of 5.4% and 4.5% in 2000and 2001.) The AMA is trying to get the CMS to make some administrative changesin the way the MEI and SGR are calculated—changes that perhaps would result ina zero change in 2002. But in a letter to medical specialty societies, RobertGilmore, MD, an AMA official, said, "I cannot overemphasize how difficultthis battle could be."

Recent Videos
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Two experts are featured in this series.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
Related Content